Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Kansas Medical Center
Women who are scheduled to take tirzepatide for weight loss will be assessed before and after taking drug for change in risk biomarkers. These include mammography, DXA scan, blood draw, and random periareolar fine needle aspiration (RPFNA) for acquisition of benign breast tissue.
Age
40–64
Sex
FEMALE
Healthy volunteers
Accepted
You may be eligible if
• BMI 30-45 kg/m2
* Female
* Insurance approved or likely approved for tirzepatide clinical use \*
* Additional risk factors for breast cancer other than obesity (any one or more) First or second degree with breast cancer Known high density on mammogram (heterogenous or extremely dense) Prior biopsy showing atypical hyperplasia or LCIS Prior treated DCIS Known carrier breast cancer predisposition gene mutation or known mutation in family member .
2- fold or higher estimated 10 year or lifetime risk compared to population by standard risk model (BCRAT, BCSC, IBIS
* Clinical contra-indication to incretin mimetics
* Insurance/third party has denied coverage and participant does not wish to do self-pay.
* Child-bearing potential and not on contraceptives
* Prior invasive breast cancer
* Currently taking any of the following medications: insulin, tamoxifen, raloxifene, letrozole, arimidex, exemestane, incretin mimetics.
Clareo Health | Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers
